By Mike Ward
Editor, Europe

OXFORD - The slowdown in IPO activity has not deterred investors from backing Atlas Venture's new $400 million fund - Atlas Venture IV - for investment in high growth life sciences and information technology companies in the U.S. and Europe. At least $120 million of the new fund has been earmarked for life sciences investments over the next three to four years, Rob Zegelaar, a principal at Atlas Venture, told BioCentury. This is the largest amount Atlas has committed to life sciences in any of its funds.